Last reviewed · How we verify
Ciprofloxacin 750 mg
At a glance
| Generic name | Ciprofloxacin 750 mg |
|---|---|
| Also known as | Test product (T), Oral antibiotics, Cipro |
| Sponsor | Future University in Egypt |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) (PHASE2, PHASE3)
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) (PHASE2, PHASE3)
- Success of Lesion Sterilization and Tissue Repair Therapy (PHASE4)
- Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis (PHASE4)
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension (PHASE2, PHASE3)
- Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ciprofloxacin 750 mg CI brief — competitive landscape report
- Ciprofloxacin 750 mg updates RSS · CI watch RSS
- Future University in Egypt portfolio CI